{"id":51300,"date":"2022-11-28T17:02:38","date_gmt":"2022-11-28T16:02:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\/"},"modified":"2022-11-28T17:02:38","modified_gmt":"2022-11-28T16:02:38","slug":"croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\/","title":{"rendered":"Croma Australia Pty Ltd, a subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines"},"content":{"rendered":"
\n

\nApproval is supported by positive results from three completed phase 3 trials that enrolled more than 1000 subjects in the U.S. and Europe<\/i>\n<\/p>\n

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Hugel America, Inc., (Hugel Aesthetics), today announced it received Therapeutic Goods Administration (TGA) approval for LETYBO (letibotulinumtoxinA) to treat moderate-to-severe glabellar (frown) lines in adults.\n<\/p>\n

\n“We are thrilled with the TGA\u2019s approval of LETYBO. This is a major milestone for Croma Australia as we focus on becoming a top aesthetics brand in Australia,\u201d stated James Hartman, President, Hugel Aesthetics. \u201cWe are excited to deliver quality aesthetic solutions that are accessible and attainable, and we look forward to contributing to the expansion of the Australian medical aesthetics market.”\n<\/p>\n

\nSteven Liew, world-renowned Plastic Surgeon, and Medical Director of Shape Clinic in NSW, stated, “Australia is in a unique position. We are a very small country by population, yet we are one of the top countries in adopting non-surgical rejuvenation therapy. Australians are curious and strive to look their best, perhaps due to our outdoor lifestyle. The addition of LETYBO, which TGA has recently approved, will significantly contribute to the aesthetic market. To me, it’s all about choice. It’s all about having another quality, anti-wrinkle injection to choose from; so that, as practitioners, we can provide the best outcome for our patients by assisting them to choose the best treatment for their needs.”\n<\/p>\n

\nLETYBO has been the market leader for six consecutive years in South Korea, one of the world\u2019s most dynamic aesthetic markets, and is now available in 44 countries.\n<\/p>\n

\nLETYBO is expected to be available in Australia 1H 2023. Injectors are encouraged to contact their Croma Australia account manager or email info@cromapharma.com.au<\/a> for information.\n<\/p>\n

\nINDICATION<\/b>\n<\/p>\n

\nLETYBO is indicated for temporary improvement in the appearance of moderate to severe glabellar frown lines in adults.\n<\/p>\n

\nHealthcare professionals and patients can contact Hugel\u2019s Medical Information team for further information at medinfoau@hugel-aesthetics.com<\/a> or by phone at 1800 276 622.\n<\/p>\n

\nAbout Hugel Aesthetics\/Croma Australia<\/b>\n<\/p>\n

\nCroma Australia Pty Ltd is a subsidiary of Hugel Aesthetics, a division of the global medical aesthetics leader, Hugel, Inc., focused on commercializing a synergistic aesthetic portfolio in the United States, Canada, and Australia. Hugel Aesthetics is dedicated to making a difference by transforming patient experiences. For more information, visit us at www.hugel-aesthetics.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nKayleigh Adam, <\/b>Alison Brod Marketing Communications, kayleigh@abmc-us.com<\/a>
Peta Roberts, Croma Australia, peta.roberts@cromapharma.com.au<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Approval is supported by positive results from three completed phase 3 trials that enrolled more than 1000 subjects in the U.S. and Europe NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Hugel America, Inc., (Hugel Aesthetics), today announced it received Therapeutic Goods Administration (TGA) approval for LETYBO (letibotulinumtoxinA) to treat moderate-to-severe glabellar (frown) lines in adults. “We are thrilled with … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51300","6":"format-standard","7":"category-industry"},"yoast_head":"\nCroma Australia Pty Ltd, a subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Croma Australia Pty Ltd, a subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Approval is supported by positive results from three completed phase 3 trials that enrolled more than 1000 subjects in the U.S. and Europe NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Hugel America, Inc., (Hugel Aesthetics), today announced it received Therapeutic Goods Administration (TGA) approval for LETYBO (letibotulinumtoxinA) to treat moderate-to-severe glabellar (frown) lines in adults. “We are thrilled with ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-28T16:02:38+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Croma Australia Pty Ltd, a subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines\",\"datePublished\":\"2022-11-28T16:02:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\\\/\"},\"wordCount\":429,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\\\/\",\"name\":\"Croma Australia Pty Ltd, a subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-11-28T16:02:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Croma Australia Pty Ltd, a subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Croma Australia Pty Ltd, a subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\/","og_locale":"en_US","og_type":"article","og_title":"Croma Australia Pty Ltd, a subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines - Pharma Trend","og_description":"Approval is supported by positive results from three completed phase 3 trials that enrolled more than 1000 subjects in the U.S. and Europe NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Hugel America, Inc., (Hugel Aesthetics), today announced it received Therapeutic Goods Administration (TGA) approval for LETYBO (letibotulinumtoxinA) to treat moderate-to-severe glabellar (frown) lines in adults. “We are thrilled with ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-28T16:02:38+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Croma Australia Pty Ltd, a subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines","datePublished":"2022-11-28T16:02:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\/"},"wordCount":429,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\/","url":"https:\/\/pharma-trend.com\/en\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\/","name":"Croma Australia Pty Ltd, a subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-11-28T16:02:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/croma-australia-pty-ltd-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Croma Australia Pty Ltd, a subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51300"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51300\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}